Yahoo Finance20d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
The study achieved its primary endpoint — treatment with the drug ... Pfizer this year in the hemophilia space. Earlier in July, the FDA approved Durveqtix (fidanacogene elaparvovec), the ...
Reuters18d
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...
FierceBiotech29d
Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy Beqvez. But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue ...
Yahoo Finance16d
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market ...
WebMD9d
FDA Approves New SVT Drug for Critical Care Use
The FDA has approved Rapiblyk ... Rapiblyk, the brand name for landiolol, is an injectable drug that slows the heart rate by blocking adrenaline's action on beta-1 receptors in the heart.
Business Wire21d
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
1 Diagnosed in early childhood, hemophilia inhibits the blood’s ... the FDA at 1-800-FDA-1088. Disclosure notice The information contained in this release is as of November 20, 2024. Pfizer ...
The Business Journals16d
FDA approves Palo Alto biotech's heart disease drug
The drug, marketed under the name Attruby, was proven under testing to postpone the hospitalizations for people living with the disease. STORY HIGHLIGHTS FDA approved BridgeBio's new heart disease ...
Yahoo Finance20d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...